Oruka Therapeutics Sets Oct. 26 Call to Share Week 16 ORKA-001 Data from EVERLAST-B Psoriasis Trial
Market Chameleon (Mon, 26-Oct 11:10 AM)
Oruka’s ORKA-001 posts 61% complete skin clearance at Week 16 in EVERLAST-B psoriasis trial
Market Chameleon (Mon, 26-Oct 7:28 AM)
BTIG Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)
at www.tipranks.com (Mon, 26-Oct 8:37 PM)
Oruka Therapeutics Reports Strong Phase 2b Psoriasis Results
at www.tipranks.com (Mon, 26-Oct 8:33 AM)
Oruka’s ORKA-001 posts rising Week 28 skin-clearance rates with no dosing after Week 4
Market Chameleon (Wed, 23-Sep 7:54 AM)
